本研究聚焦于肾透明细胞癌（ccRCC），通过单细胞ATAC-seq技术揭示其表观遗传特征，为肿瘤发生机制提供了新见解，为未来治疗提供参考。 肾透明细胞癌（ccRCC）是泌尿系统最常见的恶性肿瘤之一，其发生和进展与表观遗传调控密切相关。染色质可及性作为表观 ...

Unlike RNA sequencing, which provides information about the genes that are being expressed, ATAC-Seq (A(ssay for) T(ransposase)-A(ccessible) C(hromatin using) Seq(uencing)) provides a genome-wide ...

本研究通过单细胞ATAC-seq技术，解析了肾透明细胞癌（ccRCC）的染色质可及性特征，揭示了肿瘤细胞及相关细胞亚群的表观遗传调控机制，为ccRCC的治疗提供了新的策略。 肾透明细胞癌（ccRCC）是泌尿系统中最常见的恶性肿瘤之一，其遗传特征与肿瘤异质性和遗传 ...

10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement ...

The 10X Genomics Chromium System is available for multiple single cell product lines: Single Cell Gene Expression, High Definition Immunology, Single Cell CNV, and Single Cell ATAC-seq. For more ...

Parse Biosciences affirms plans to proceed with development and future release of their Evercode™ single cell chromatin products.

Henriksson believes that the technique for analyzing genomes from single cells (ATAC-seq) needs to be reevaluated. ATAC-seq uses a type of genetically modified mobile gene sequence, called a ...

We can help with the submission process and also assist you with raw data transfer, processing, and analysis. We can help with data processing and custom analysis for most genomic data - including ...

On February 12, 2025, the United States District Court for the District of Delaware denied defendant Parse Biosciences’s (“Parse”) motions for ...

a global leader in life science research and clinical diagnostic products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) services, featuring Bio-Rad’s ...

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...